Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market

Bruce RD; Govindasamy S; Sylla L; Kamarulzaman A; Altice FL

doi:10.1080/00952990802585406

Fulltext

Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/naloxone to the Malaysian market

Bruce RD , Govindasamy S , Sylla L , Kamarulzaman A , Altice FL

Am J Drug Alcohol Abuse, 2009;35(2):68-72.

PMID: 19212931 DOI: 10.1080/00952990802585406

Abstract

Diversion of buprenorphine (BPN) has been described in settings where it is legally prescribed and has resulted in increasing concern. To address this concern, co-formulation of buprenorphine/naloxone (BPN/NLX) replaced buprenorphine alone in Malaysia in December 2006.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.